HIV ÀÚ°¡ °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, ±â¼úº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
HIV Self-testing Market Size, Share & Trends Analysis Report By Type (Blood-based Kits, Saliva-based Kits), By Technology (Immunofiltration Assays, Lateral Flow Assays (LFA)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813927
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,431,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,848,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,683,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

HIV ÀÚ°¡ °Ë»ç ½ÃÀå ¿ä¾à

Àü ¼¼°è HIV ÀÚ°¡ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 2¾ï 1,155¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2033³â¿¡´Â 6¾ï 4,341¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2033³â±îÁö 13.55%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº HIV Á¶±â ¹ß°ß¿¡ ´ëÇÑ Á߿伺ÀÌ Á¡Á¡ ´õ °­Á¶µÇ°í, HIV À¯º´·üÀÌ »ó½ÂÇϰí, °³ÀÎÀûÀÌ°í ºñ¹ÐÀÌ º¸ÀåµÇ´Â °Ç°­ ¼Ö·ç¼ÇÀ¸·Î Àü ¼¼°èÀûÀ¸·Î À̵¿ÇÏ´Â Ãß¼¼¿¡ ÈûÀÔ¾î ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

100°³±¹ ÀÌ»óÀÌ HIVST Á¤Ã¥À» äÅÃÇϰí, 2023³â ÇÑ ÇØ¿¡¸¸ 2,000¸¸ °³ ÀÌ»óÀÇ Å°Æ®°¡ Àü ¼¼°è¿¡ ¹èÆ÷µÇ¾ú½À´Ï´Ù. ½Å¼Ó Áø´Ü ŰƮ´Â Àú·ÅÇÑ °¡°Ý°ú È®À强À¸·Î ÀÎÇØ ¼±Áø±¹°ú °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ÃßÁ¤¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î ¾à 4,080¸¸ ¸íÀÌ HIV¿¡ °¨¿°µÇ¾î ÀÖÀ¸¸ç, ±× Áß 0-14¼¼ ¾î¸°À̰¡ 1,400¸¸ ¸í¿¡ ´ÞÇÕ´Ï´Ù. 2024³â ÇÑ ÇØ¿¡¸¸ ½Å±Ô HIV °¨¿°ÀÚ´Â ¾à 130¸¸ ¸íÀ̸ç, ±× Áß 12¸¸ ¸íÀÌ ¾î¸°ÀÌÀÔ´Ï´Ù. °°Àº ÇØ¿¡ ¾à 63¸¸ ¸íÀÌ HIV °ü·Ã ¿øÀÎÀ¸·Î »ç¸ÁÇßÀ¸¸ç, ±× Áß 7¸¸5,000¸íÀÇ ¾î¸°À̰¡ Æ÷ÇԵǾú½À´Ï´Ù. HIVÀÇ À¯ÇàÀÌ ½ÃÀÛµÈ ÀÌ·¡·Î 4,410¸¸ ¸íÀÌ HIV °ü·Ã Áúº´À¸·Î ¸ñ¼ûÀ» ÀÒÀº °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÇöÀçµµ ±× ¿µÇâÀº °è¼ÓµÇ°í ÀÖÁö¸¸, Áö³­ 10³â ¹Ý µ¿¾È Àü ¼¼°èÀûÀ¸·Î »ó´çÇÑ ÁøÀüÀÌ ÀÖ¾ú½À´Ï´Ù. 2010³âºÎÅÍ 2024³â±îÁö ½Å±Ô HIV °¨¿°ÀÚ ¼ö´Â ¾à 40% °¨¼ÒÇÏ¿© ¿¬°£ 220¸¸ ¸í¿¡¼­ 130¸¸ ¸íÀ¸·Î °¨¼ÒÇß½À´Ï´Ù. °°Àº ±â°£ µ¿¾È HIV °ü·Ã »ç¸ÁÀÚ´Â 54% °¨¼ÒÇÏ¿© 140¸¸ ¸í¿¡¼­ 63¸¸ ¸íÀ¸·Î ÁÙ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¼Ò´Â HIV¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, ¿¹¹æ ³ë·Â, Ç×·¹Æ®·Î¹ÙÀÌ·¯½º Ä¡·áÀÇ È®´ë, HIV ÀÚ°¡Áø´Ü°ú °°Àº Àü·«ÀÇ È®´ë, Á¶±â Áø´Ü ¹× Ä¡·á ½ÃÀÛÀÇ Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

HIV ÀÚ°¡Áø´Ü ½ÃÀåÀÇ °­·ÂÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â ´«¿¡ Àß ¶çÁö ¾Ê°í, Á¢±ÙÀÌ ¿ëÀÌÇϸç, »ç¿ëÇϱ⠽¬¿î Áø´Ü ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ Ŭ¸®´Ð ±â¹Ý °Ë»ç¿¡ ´ëÇÑ Æí°ß°ú À庮¿¡ Á÷¸éÇÑ Áý´Ü¿¡¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. UNAIDS¿¡ µû¸£¸é, Àü ¼¼°è HIV °¨¿°ÀÚÀÇ 40%°¡ ¹ÌÁø´Ü »óÅ·Π³²¾Æ ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ °ÝÂ÷´Â ÁÖ·Î Â÷º°¿¡ ´ëÇÑ µÎ·Á¿ò, »çȸÀû Æí°ß, ÀÇ·á ½Ã¼³¿¡ ´ëÇÑ Á¢±ÙÀÇ ºÒÆíÇÔ¿¡¼­ ±âÀÎÇÑ´Ù°í ÇÕ´Ï´Ù. HIV ÀÚ°¡ °Ë»ç´Â °³ÀÎÀÌ µÎ·Á¿ò ¾øÀÌ ÀÚ½ÅÀÇ »óŸ¦ ¾Ë ¼ö ÀÖ´Â °³ÀÎÀûÀÌ°í °¡Á¤ÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. OraQuick ÀçÅà HIV °Ë»ç¿Í °°Àº Ÿ¾× ±â¹Ý ŰƮ´Â ºñħ½À¼º, °£Æí¼º, 20ºÐ ³» °á°ú Ç¥½Ã·Î Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä« µî HIV °¨¿°·üÀÌ °¡Àå ³ôÀº Áö¿ª¿¡¼­´Â ÀÚ°¡ °Ë»ç°¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÄɳÄ, ¸»¶óÀ§, ³²¾ÆÇÁ¸®Ä«°øÈ­±¹°ú °°Àº ±¹°¡µéÀº Áö¿ª»çȸ ¹× NGO ¹èÆ÷¸¦ ÅëÇØ ±¹°¡Àû HIVST ÇÁ·Î±×·¥À» È®´ëÇØ¿Ô½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â E-Commerce°¡ Ȱ¼ºÈ­µÇ¸é¼­ ¿Â¶óÀÎ ¾à±¹À» ÅëÇØ HIV ÀÚ°¡ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÍ¸í¼º, ÆíÀǼº, ±â¼úÀû °£ÆíÇÔÀÇ Á¶ÇÕÀº Áø´ÜÀ²À» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó °øÁߺ¸°Ç ½Ã½ºÅÛÀÌ HIV ¿¹¹æ ¹× Ä¡·á ¿¬°è¿¡ Á¢±ÙÇÏ´Â ¹æ½ÄÀ» ±Ùº»ÀûÀ¸·Î º¯È­½Ã۰í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀ¸·Î HIV ÀÚ°¡ °Ë»ç´Â º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ »ç¿ëÀÚ Áß½ÉÀÇ ÇÁ·Î¼¼½º·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. °¡Àå ÀϹÝÀûÀÎ ÇüÅÂÀÎ Ãø¸é È帧 ¸é¿ª ÃøÁ¤¹ý(LFA)Àº Ÿ¾×À̳ª ¼Õ°¡¶ôÀ¸·Î Â Ç÷¾× »ùÇÿ¡¼­ HIV-1/2 Ç×ü¸¦ °ËÃâÇÏ´Â °£´ÜÇÑ ½ºÆ®¸³À» »ç¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â 15-20ºÐÀÌ¸é °á°ú¸¦ ¾òÀ» ¼ö ÀÖÀ¸¸ç, »õ·Î¿î Àåºñ¿¡´Â ·£½Ë, ¹öÆÛ, ½ºÆ®¸³À» ÇϳªÀÇ Àåºñ¿¡ ÅëÇÕÇÑ AtomoÀÇ HIV ÀÚ°¡Áø´Ü°ú °°Àº ¿ÃÀοø ÅëÇÕ ½Ã½ºÅÛÀÌ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½º¸¶Æ®Æù°ú ¿¬µ¿µÈ µðÁöÅÐ ÀÚ°¡ °Ë»ç°¡ ½Ã¹üÀûÀ¸·Î µµÀÔµÇ¾î »ç¿ëÀÚ°¡ °á°ú¸¦ ½ºÄµÇϰí, ¾È³»¸¦ ¹Þ°í, ¿ø°ÝÀÇ·á ¼­ºñ½º¿¡ Á¢¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ ½º¸¶Æ®ÆùÀ» ÀÌ¿ëÇÑ ÆÇµ¶Àº ÈÆ·ÃµÈ ½Ã°¢Àû ÇØ¼®°ú 98% ÀÌ»ó ÀÏÄ¡ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì¼¼À¯Ã¼ °øÇÐ ¹× ³ª³ë ±â¹Ý °ËÃâÀÇ ±â¼ú Çõ½ÅÀº ¹Ì·¡ÀÇ HIVST ŰƮ¸¦ ´õ¿í ¹Î°¨Çϰí Á¶±â °¨¿°¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ¾à¼ÓÇϰí ÀÖ½À´Ï´Ù. ¾÷°è´Â ¶ÇÇÑ Æ¯È÷ µ¿½Ã °¨¿°ÀÌ ¸¹Àº Áö¿ª¿¡¼­´Â Á¶ÇÕ Å°Æ®(HIV+¸Åµ¶ µî)·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû °³¼±Àº ÀÎÀû ¿À·ù¸¦ °¨¼Ò½Ãų »Ó¸¸ ¾Æ´Ï¶ó ¹®¸Í·üÀÌ ³·Àº Áý´Ü¿¡¼­µµ ÀÚ°¡ °Ë»ç°¡ °¡´ÉÇØÁ® Àü ¼¼°èÀûÀ¸·Î º¸±ÞÀÌ ´õ¿í È®´ëµÉ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : ÁÖ¿ä ¿ä¾à

Á¦3Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : À¯Åë ä³Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå HIV ÀÚ°¡ °Ë»ç ½ÃÀå : Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦8Àå °æÀï ±¸µµ

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

HIV Self-testing Market Summary

The global HIV Self-testing market size was estimated at USD 211.55 million in 2024 and is expected to reach USD 643.41 million by 2033, growing at a CAGR of 13.55% from 2025 to 2033. This growth is fueled by an increasing emphasis on early HIV detection, rising HIV prevalence, and a global shift toward personal, confidential health solutions.

Over 100 countries have adopted HIVST policies, and more than 20 million kits were distributed globally in 2023 alone. The affordability and scalability of rapid diagnostic kits have made them integral in both developed and developing health systems. As of the most recent estimates, approximately 40.8 million people worldwide are living with HIV, including 1.4 million children between the ages of 0 and 14. In 2024 alone, there were about 1.3 million new HIV infections, with 120,000 cases occurring in children. That same year, an estimated 630,000 people died from HIV-related causes, including 75,000 children. Since the beginning of the HIV epidemic, it is estimated that 44.1 million people have lost their lives due to HIV-related illnesses. Despite the ongoing impact, global progress has been substantial over the past decade and a half. Between 2010 and 2024, the number of new HIV infections decreased by approximately 40%, dropping from 2.2 million to 1.3 million annually. During the same period, HIV-related deaths fell by 54%, declining from 1.4 million to 630,000. These reductions reflect the success of widespread awareness, prevention efforts, antiretroviral therapy scale-up, and increasing adoption of strategies such as HIV self-testing, which have contributed to earlier diagnosis and treatment initiation.

One of the strongest drivers of the HIV self-testing market is the rising demand for discreet, accessible, and user-friendly diagnostic options, particularly in populations facing stigma or barriers to clinic-based testing. According to UNAIDS, nearly 40% of people living with HIV globally remain undiagnosed, a gap largely attributed to fear of discrimination, social stigma, and inconvenient access to health facilities. HIV self-tests provide a private, at-home alternative that empowers individuals to know their status without fear. Saliva-based kits such as OraQuick In-Home HIV Test have become popular for their non-invasive nature, simplicity, and 20-minute result window. In regions such as Sub-Saharan Africa, where HIV prevalence is highest, self-testing has been pivotal: countries like Kenya, Malawi, and South Africa have scaled up national HIVST programs through community and NGO distribution. In high-income countries, rising e-commerce penetration has enabled widespread access to HIV self-tests via online pharmacies. This combination of anonymity, convenience, and technological simplicity is not only improving diagnosis rates but also fundamentally shifting how public health systems approach HIV prevention and treatment linkage.

Technological advancements are transforming HIV self-testing into a more accurate, efficient, and user-centric process. The most common format-lateral flow immunoassays (LFA)-uses a simple strip that detects HIV-1/2 antibodies through a saliva or finger-prick blood sample. These tests deliver results in 15-20 minutes, and newer devices incorporate all-in-one integrated systems, such as Atomo's HIV Self-Test, which combines lancet, buffer, and strip in a single device. In addition, smartphone-linked digital self-tests are being piloted, allowing users to scan results, receive guided instructions, and access telehealth services-enhancing test reliability and post-test linkage to care. In clinical trials, smartphone-based readers have shown >98% concordance with trained visual interpretation. Furthermore, innovations in microfluidics and nano-based detection promise to make future HIVST kits even more sensitive and early-stage infection-aware. The industry is also shifting toward combination kits (e.g., HIV + syphilis), especially in areas with co-infection burdens. These technological improvements not only reduce human error but also make self-testing viable in low-literacy populations, further expanding its global reach.

Global HIV Self-testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HIV self-testing market based on type, technology, distribution channel, and region:

Table of Contents

Chapter 1. HIV Self-testing Market: Methodology and Scope

Chapter 2. HIV Self-testing Market: Executive Summary

Chapter 3. HIV Self-testing Market Variables, Trends, & Scope

Chapter 4. HIV Self-testing Market: Type Estimates & Trend Analysis

Chapter 5. HIV Self-testing Market: Technology Estimates & Trend Analysis

Chapter 6. HIV Self-testing Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. HIV Self-testing Market: Regional Business Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â